Table 3. Assessment response to tyrosine kinase inhibitor therapy.
BCR, breakpoint cluster region; ABL, Abelson murine leukemia; mRNA, messenger ribonucleic acid.
BCR, breakpoint cluster region; ABL, Abelson murine leukemia; mRNA, messenger ribonucleic acid.